AR040781A1 - Compuestos 5-sustituidos de 7,9 -difluoruro- 5 h- cromeno [3 ,4-f] quinolina como compuestos moduladores selectivos de receptores de progesterona y composicion farmaceutica - Google Patents
Compuestos 5-sustituidos de 7,9 -difluoruro- 5 h- cromeno [3 ,4-f] quinolina como compuestos moduladores selectivos de receptores de progesterona y composicion farmaceuticaInfo
- Publication number
- AR040781A1 AR040781A1 AR20030102794A ARP030102794A AR040781A1 AR 040781 A1 AR040781 A1 AR 040781A1 AR 20030102794 A AR20030102794 A AR 20030102794A AR P030102794 A ARP030102794 A AR P030102794A AR 040781 A1 AR040781 A1 AR 040781A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- alkyl
- group
- hydrogen
- haloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003998 progesterone receptors Human genes 0.000 title abstract 2
- 108090000468 progesterone receptors Proteins 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000232 haloalkynyl group Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010027514 Metrorrhagia Diseases 0.000 abstract 1
- 206010067269 Uterine fibrosis Diseases 0.000 abstract 1
- 239000004015 abortifacient agent Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 229940124558 contraceptive agent Drugs 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 230000004720 fertilization Effects 0.000 abstract 1
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41796802P | 2002-10-11 | 2002-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040781A1 true AR040781A1 (es) | 2005-04-20 |
Family
ID=31994318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102794A AR040781A1 (es) | 2002-10-11 | 2003-08-04 | Compuestos 5-sustituidos de 7,9 -difluoruro- 5 h- cromeno [3 ,4-f] quinolina como compuestos moduladores selectivos de receptores de progesterona y composicion farmaceutica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7163946B2 (enExample) |
| EP (1) | EP1554283A1 (enExample) |
| JP (1) | JP2006504737A (enExample) |
| AR (1) | AR040781A1 (enExample) |
| AU (1) | AU2003258051A1 (enExample) |
| CA (1) | CA2501834A1 (enExample) |
| CL (1) | CL2003001545A1 (enExample) |
| DE (1) | DE20301728U1 (enExample) |
| HK (1) | HK1055059A2 (enExample) |
| MX (1) | MXPA05003801A (enExample) |
| TW (1) | TW200413384A (enExample) |
| WO (1) | WO2004033461A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
| HK1055058A2 (en) | 2002-10-11 | 2003-12-05 | Ligand Pharmaceuticals Incorporated | 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
| CA2501833A1 (en) * | 2002-10-11 | 2004-04-22 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
| LT3820874T (lt) * | 2018-07-12 | 2023-02-10 | Eli Lilly And Company | Selektyvūs estrogenų receptorių skaidytojai |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635941A (en) | 1969-04-01 | 1972-01-18 | Eastman Kodak Co | Disperse mono azo dyes containing an acylamidotetrahydroquinoline group |
| US3907507A (en) | 1971-04-26 | 1975-09-23 | Heliodoro Monroy Rivera | Novel apparatus for the obtention of substituted 1,2-dihydroquinolines |
| DK1130017T3 (da) | 1990-11-30 | 2005-10-10 | Otsuka Pharma Co Ltd | Azolderivater og deres anvendelse som superoxidradikalinhibitorer |
| JPH04316557A (ja) | 1991-04-16 | 1992-11-06 | Kyorin Pharmaceut Co Ltd | ６−アリール環状アントラニル酸誘導体 |
| US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
| US5693647A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| CZ176197A3 (cs) | 1994-12-22 | 1998-09-16 | Ligand Pharmaceuticals Incorporated | Modulátory steroidových receptorů a způsoby jejich přípravy a použití |
| US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
| RU2214412C2 (ru) | 1996-06-27 | 2003-10-20 | Лиганд Фармасетикалз Инкорпорейтед | ПРОИЗВОДНЫЕ 8-ПИРИДОНО [5,6g] ХИНОЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБЫ С ИХ ИСПОЛЬЗОВАНИЕМ |
| US6380207B2 (en) | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
| BR9907788A (pt) * | 1998-02-13 | 2001-10-30 | Abbott Lab | Agentes antiinflamatórios seletivos paraglicocorticóides |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| US6093826A (en) | 1998-06-08 | 2000-07-25 | Ligand Pharmaceuticals Incorporated | Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines |
| DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
| HK1055058A2 (en) | 2002-10-11 | 2003-12-05 | Ligand Pharmaceuticals Incorporated | 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
| CA2501833A1 (en) | 2002-10-11 | 2004-04-22 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
-
2003
- 2003-02-04 DE DE20301728U patent/DE20301728U1/de not_active Expired - Lifetime
- 2003-08-04 AR AR20030102794A patent/AR040781A1/es not_active Application Discontinuation
- 2003-08-04 HK HK03105598A patent/HK1055059A2/xx not_active IP Right Cessation
- 2003-08-04 MX MXPA05003801A patent/MXPA05003801A/es unknown
- 2003-08-04 CA CA002501834A patent/CA2501834A1/en not_active Abandoned
- 2003-08-04 AU AU2003258051A patent/AU2003258051A1/en not_active Abandoned
- 2003-08-04 WO PCT/US2003/024420 patent/WO2004033461A1/en not_active Ceased
- 2003-08-04 JP JP2004543233A patent/JP2006504737A/ja active Pending
- 2003-08-04 EP EP03808052A patent/EP1554283A1/en not_active Withdrawn
- 2003-08-04 TW TW092121283A patent/TW200413384A/zh unknown
- 2003-08-04 CL CL200301545A patent/CL2003001545A1/es unknown
- 2003-10-10 US US10/684,212 patent/US7163946B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003258051A1 (en) | 2004-05-04 |
| MXPA05003801A (es) | 2005-06-08 |
| US7163946B2 (en) | 2007-01-16 |
| CL2003001545A1 (es) | 2005-01-07 |
| JP2006504737A (ja) | 2006-02-09 |
| EP1554283A1 (en) | 2005-07-20 |
| DE20301728U1 (de) | 2004-03-11 |
| WO2004033461A1 (en) | 2004-04-22 |
| CA2501834A1 (en) | 2004-04-22 |
| TW200413384A (en) | 2004-08-01 |
| HK1055059A2 (en) | 2003-12-05 |
| US20040152717A1 (en) | 2004-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| UA72917C2 (en) | Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor | |
| AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
| AR046964A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion. | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR043015A1 (es) | Compuestos moduladores de amida derivada de quinolina del receptor vanilloide vr1, composiciones farmaceuticas y veterinarias que los contienen y su uso en el tratamiento de enfermedades afectadas por la modulacion de dichos receptores | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR052215A1 (es) | 3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas, su uso en el tratamiento de enfermedades relacionadas y composiciones farmacéuticas que las contienen. | |
| AR078674A1 (es) | Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas | |
| AR035759A1 (es) | Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| MXPA05010859A (es) | Antagonistas mchr1 heterociclicos. | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| MX2007012936A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
| AR034174A1 (es) | Compuestos de benzoxazinona, procedimiento para su preparacion, composiciones farmaceuticas que lo comprenden, procedimiento para la preparacion de tales composiciones, y el uso de dichos compuestos o composiciones en la fabricacion de medicamentos | |
| EA200970704A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ | |
| ES8107201A1 (es) | Un procedimiento para la preparacion de derivados de morfo- lina | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| ATE530182T1 (de) | Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen | |
| JO2696B1 (en) | Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists | |
| AR040781A1 (es) | Compuestos 5-sustituidos de 7,9 -difluoruro- 5 h- cromeno [3 ,4-f] quinolina como compuestos moduladores selectivos de receptores de progesterona y composicion farmaceutica | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
| AR072802A1 (es) | Derivados piperidinicos de esteres de acido bifenil-2-il-carbamico, antagonistas de receptores muscarinicos m3, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de trastornos digestivos,respiratorios y/o urinarios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |